Samlowski Wolfram E, Moon James, Kuebler J Philip, Nichols Craig R, Gandara David R, Ozer Howard, Williamson Stephen K, Atkins James N, Schuller David E, Ensley John F
University of Utah Health Science Center, Salt Lake City, Utah, USA.
Cancer Invest. 2007 Apr-May;25(3):182-8. doi: 10.1080/07357900701209061.
Carboplatin/docetaxel chemotherapy was evaluated in advanced squamous cell carcinoma of the head and neck (SCCHN). Eligibility included patients with recurrent, persistent, or metastatic SCCHN with Zubrod performance status 0-2. Docetaxel 65 mg/m(2) and carboplatin (AUC of 6) were given IV in a 21-day cycle to 68 patients. Response probability was 25 percent (95%CI: 15-38). The major toxicity observed was neutropenia, with 36 patients (61 percent) experiencing Grade 3 or worse. Median progression-free survival was 3.8 months (95%CI, 3.1-4.8) Median overall survival was 7.4 months (95%CI, 6.2-8.9). The results of this study suggest this regimen is active for outpatient treatment of recurrent SCCHN patients with good performance status.
对晚期头颈部鳞状细胞癌（SCCHN）患者进行了卡铂/多西他赛化疗评估。入选标准包括复发性、持续性或转移性SCCHN且Zubrod体能状态为0 - 2的患者。68例患者接受了每21天一个周期的静脉注射，多西他赛剂量为65mg/m²，卡铂（AUC为6）。缓解概率为25%（95%CI：15 - 38）。观察到的主要毒性为中性粒细胞减少，36例患者（61%）出现3级或更严重的情况。无进展生存期的中位数为3.8个月（95%CI，3.1 - 4.8），总生存期的中位数为7.4个月（95%CI，6.2 - 8.9）。本研究结果表明，该方案对于体能状态良好的复发性SCCHN门诊患者治疗有效。
